Completion pneumonectomy of the residual left lung to treat lung cancer in a patient with hemophilia A: Report of a case

Surgery Today

Volumn 30, Issue 10, 2000, Pages 917-920

  Nomoto, Yasushi ^a   Kimura, Hideki ^a   Iwai, Naomichi ^a   Mizobuchi, Teruaki ^a   Yokoi, Sana ^a   Kumagai, Kyoya ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

Coagulation factor VIII; Hemophilia; Lung cancer; Operation; Recombinant DNA

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

AGED; ARTICLE; CASE REPORT; GERIATRIC PATIENT; HEMATOLOGICAL PARAMETERS; HEMOPHILIA; HEMOPHILIA A; HUMAN; LUNG CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MALE; POSTOPERATIVE CARE; SURGICAL PATIENT; TREATMENT OUTCOME;

EID: 0033768651     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950070045     Document Type: Article

References (14)

1. Is major surgery in hemophiliac patients safe?
2. A patient with hemophilia A in whom total gastrectomy was performed using recombinant factor VIII
3. Clinical studies on surgeries in 7 hemophiliacs
4. Obstructive ileus caused by blood clot after emergency total gastrectomy in a patient with hemophilia A: Report of a case
5. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant factor VIII study group
6. Characterization of recombinant human factor VIII (BAY w 6240) and effect of von Willebrand factor on determination of factor VIII activity
7. Structure and composition of recombinant human factor VIII produced in baby hamster kidney cells
8. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A
9. The experimental development of an ultrasonically activated scalpel for laparoscopic use
10. Tissue actions of bipolar scissors compared with monopolar devices
11. The argon beam coagulator provides rapid hemostasis of experimental hepatic and splenic hemorrhage in anticoagulated dogs
12. Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: A possible link with immunosuppressive effects in hemophiliacs
13. Hemolysis due to anti-A and anti-B in factor VIII preparations
14. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII